GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Celyad Oncology SA (XBRU:CYAD) » Definitions » Enterprise Value

Celyad Oncology (XBRU:CYAD) Enterprise Value : €8.01 Mil (As of May. 22, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Celyad Oncology Enterprise Value?

Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Celyad Oncology's Enterprise Value is €8.01 Mil. Celyad Oncology's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 was €-13.93 Mil. Therefore, Celyad Oncology's EV-to-EBIT ratio for today is -0.57.

EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Celyad Oncology's Enterprise Value is €8.01 Mil. Celyad Oncology's EBITDA for the trailing twelve months (TTM) ended in Jun. 2023 was €-13.93 Mil. Therefore, Celyad Oncology's EV-to-EBITDA ratio for today is -0.57.

EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Celyad Oncology's Enterprise Value is €8.01 Mil. Celyad Oncology's Revenue for the trailing twelve months (TTM) ended in Jun. 2023 was €0.00 Mil. Therefore, Celyad Oncology's EV-to-Revenue ratio for today is .


Celyad Oncology Enterprise Value Historical Data

The historical data trend for Celyad Oncology's Enterprise Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Celyad Oncology Enterprise Value Chart

Celyad Oncology Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Enterprise Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 150.03 100.27 78.70 52.03 -0.76

Celyad Oncology Quarterly Data
Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Dec22 Jun23
Enterprise Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 52.03 30.24 27.05 -0.76 7.35

Competitive Comparison of Celyad Oncology's Enterprise Value

For the Biotechnology subindustry, Celyad Oncology's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Celyad Oncology's Enterprise Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Celyad Oncology's Enterprise Value distribution charts can be found below:

* The bar in red indicates where Celyad Oncology's Enterprise Value falls into.



Celyad Oncology Enterprise Value Calculation

Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

Celyad Oncology's Enterprise Value for the fiscal year that ended in Dec. 2022 is calculated as

Celyad Oncology's Enterprise Value for the quarter that ended in Jun. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Celyad Oncology  (XBRU:CYAD) Enterprise Value Explanation

When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.

If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.

The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.

For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.

Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.

1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.

Celyad Oncology's EV-to-EBIT for today is

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=8.009/-13.929
=-0.57

Celyad Oncology's current Enterprise Value is €8.01 Mil.
Celyad Oncology's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-13.93 Mil.

2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.

Celyad Oncology's EV-to-EBITDA for today is:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA(TTM)
=8.009/-13.929
=-0.57

Celyad Oncology's current Enterprise Value is €8.01 Mil.
Celyad Oncology's EBITDA for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-13.93 Mil.

3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.

Celyad Oncology's EV-to-Revenue for today is:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=8.009/0
=

Celyad Oncology's current Enterprise Value is €8.01 Mil.
Celyad Oncology's Revenue for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Celyad Oncology Enterprise Value Related Terms

Thank you for viewing the detailed overview of Celyad Oncology's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Celyad Oncology (XBRU:CYAD) Business Description

Traded in Other Exchanges
Address
Rue Edouard Belin 2, Axis Business Park, Brabant Wallon, Mont-Saint-Guibert, BEL, 1435
Celyad Oncology SA is a biopharmaceutical company focused on the discovery and development of innovative technologies for chimeric antigen receptor T-cell (CAR T) therapies. The company focuses on solid tumors and hematological malignancies. The firm has CYAD-01 and CYAD-02 programs in the pipeline. The company owns trademarks and service marks including CELYAD, C-CATH, C_CURE, CAR-T Cell, THINK, CYAD01 - Deplethink, CYAD02 - Cycle1, CwalityCAR, CYAD-101, and new engagers. The firm has Cardiology and Immuno-oncology operating segments.

Celyad Oncology (XBRU:CYAD) Headlines

No Headlines